On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research tools and early-stage vaccine and diagnostic candidates to the Medicines Patent Pool (MPP) through the World Health Organizationﾒs COVID-19 Technology Access Pool.

The licenses allowed manufacturers from all around the world to work with MPP and C-TAP to use these technologies for the potential development of COVID-19 vaccines, treatments, and diagnostics to benefit people living in low- and middle-income countries.